Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Common Equity: 2015-2025

Historic Common Equity for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $13.5 million.

  • Editas Medicine's Common Equity fell 92.34% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 92.34%. This contributed to the annual value of $134.3 million for FY2024, which is 61.54% down from last year.
  • Latest data reveals that Editas Medicine reported Common Equity of $13.5 million as of Q3 2025, which was down 29.89% from $19.2 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Common Equity ranged from a high of $638.0 million in Q1 2021 and a low of $13.5 million during Q3 2025.
  • Over the past 3 years, Editas Medicine's median Common Equity value was $232.0 million (recorded in 2024), while the average stood at $214.4 million.
  • Per our database at Business Quant, Editas Medicine's Common Equity skyrocketed by 171.99% in 2021 and then plummeted by 92.34% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's Common Equity stood at $553.6 million in 2021, then plummeted by 34.85% to $360.7 million in 2022, then decreased by 3.21% to $349.1 million in 2023, then slumped by 61.54% to $134.3 million in 2024, then plummeted by 92.34% to $13.5 million in 2025.
  • Its Common Equity stands at $13.5 million for Q3 2025, versus $19.2 million for Q2 2025 and $62.4 million for Q1 2025.